Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity.

Front Med (Lausanne) · 2026 · PMC12960177 · PMID 41797776

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

Aggressive ROP (A-ROP) (OR = 3.009, p = 0.106) and a history of systemic surgery (OR = 2.293, p = 0.095) showed a trend being associated with increased risk but did not reach statistical significance in this study.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.